Carole Diane Mitnick, Sc.D.
Co-Author
This page shows the publications co-authored by Carole Mitnick and Meredith Brooks.
Connection Strength
2.800
-
Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis. Int J Tuberc Lung Dis. 2017 01 01; 21(1):6-11.
Score: 0.346
-
Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. Glob Pediatr Health. 2016; 3:2333794X16674382.
Score: 0.342
-
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453.
Score: 0.338
-
Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses. PLoS One. 2020; 15(10):e0240297.
Score: 0.225
-
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168.
Score: 0.203
-
Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 2019 Mar 21; 9(1):32-41.
Score: 0.202
-
Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts. BMC Med Res Methodol. 2018 12 11; 18(1):166.
Score: 0.198
-
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
Score: 0.194
-
Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12.
Score: 0.172
-
(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 12 01; 20(12):18-23.
Score: 0.172
-
Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 10; 48(4):1160-1170.
Score: 0.169
-
Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis". Antimicrob Agents Chemother. 2017 09; 61(9).
Score: 0.090
-
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8).
Score: 0.090
-
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB. Int J Tuberc Lung Dis. 2021 07 01; 25(7):596-598.
Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.